Compare Dicks Sporting Goods Inc (DKS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Sana Biotechnology Inc — how do they compare? Dicks Sporting Goods Inc trades at $202.67 (market cap $18.35B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Dicks Sporting Goods Inc is far larger — about 16.2× Sana Biotechnology Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DKS | SANA | |
|---|---|---|
Market Cap | $18.35B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $5.92 |
52-Week Low | $187.78 | $2.68 |
Enterprise Value | $25.14B | $1.05B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $202.66, down 5.34% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a 4.71% net income margin and 20.9% ROE, while analyst consensus remains strongly bullish with a $263.22 price target. Recent news highlights DKS as a value stock pick with accelerating sales growth, though the stock faces near-term technical pressure.
The outlook remains positive given strong analyst support and consistent earnings performance, but investors should monitor the bearish technical indicators and upcoming Q2 2026 earnings report on August 25th. Key risks include retail sector competition and potential margin pressure as revenue growth outpaces profit growth in 2026 projections.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
